Pyrrolidines
This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutically acceptable derivatives thereof, to their use in medicine, to compositions containing them, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. In particular the compounds of formula (I) are useful for the treatment of EP2-mediated conditions, such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), chronic pelvic pain syndrome.
1. A compound of formula (I):
wherein:
R 1 is a phenyl group optionally substituted by one or two substituents independently selected from F, Cl, Br, CN, C 1-4 alkyl, C 1-4 alkylthio and C 1-4 alkoxy, fluoro-C 1-6 alkyl and fluoro-C 1-6 alkoxy, or a C 3-6 cycloalkyl group;
X represents a direct link, NH, or O;
Z is selected from
R 2 is H or C 1-6 alkyl (optionally substituted with 1 to 3 fluorine atoms);
R 3 is C 1-6 alkyl (optionally substituted with 1 to 3 fluorine atoms);
Ar is an aromatic group consisting of 1, 2 or 3 aromatic rings, which aromatic rings are independently selected from phenyl and a 5- or 6-membered heteroaromatic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, and which aromatic rings, if there are 2 or more, can be fused or linked by one or more covalent bond, and which aromatic rings are optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, CN, OH, C 1-6 alkyl, C 1-6 alkylthio, fluoro-C 1-6 alkyl, fluoro-C 1-6 alkylthio, fluoro-C 1-6 alkoxy, C 1-6 alkoxy, SO 2 R 4 , NR 5 R 6 , NHSO 2 R 7 , SO 2 NR 8 R 9 , and NHCOR 12 ;
R 4 and R 7 are each independently C 1-6 alkyl (optionally substituted by 1 to 3 fluorine atoms);
R 5 , R 6 , R 8 , R 9 , R 10 , R 11 and R 12 are each independently H or C 1-6 alkyl (optionally substituted by 1 to 3 fluorine atoms);
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein R 1 is a phenyl group optionally substituted by one or two substituents independently selected from F, Cl and C 1-4 alkoxy, or a C 3-6 cycloalkyl group, or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1 , wherein X represents a direct link, or a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 wherein Z is
or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 4 , wherein R 2 is H, or a pharmaceutically acceptable salt thereof.
6. A compound according to claim 1 , wherein Ar is a biphenyl, pyridinylphenyl, pyrimidinylphenyl or pyrazinylphenyl group, optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, CN, OH, C 1-6 alkyl, C 1-6 alkylthio, fluoro-C 1-6 alkyl, fluoro-C 1-6 alkylthio, fluoro-C 1-6 alkoxy, C 1-6 alkoxy, SO 2 R 4 , NR 5 R 6 , NHSO 2 R 7 , SO 2 NR 8 R 9 , CONR 10 R 11 and NHCOR 12 , or a pharmaceutically acceptable salt thereof.
7. A compound according to claim 6 , wherein Ar is a biphenyl, pyridinylphenyl, pyrimidinylphenyl or pyrazinylphenyl optionally substituted by 1, 2 or 3 substitutents independently selected from F, Cl, CN, and a C 1-6 alkoxy group, or a pharmaceutically acceptable salt thereof.
8. A compound according to claim 1 , which is a compound of formula (Ia)
or a pharmaceutically acceptable salt thereof.
9. A compound according to claim 1 , which is a compound of formula (Ib)
or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, carrier or adjuvant.
11. A method of treating endometriosis, uterine fibroids, menorrhagia, adenomyosis, primary dysmenorrhoea and secondary dysmenorrhoea or, chronic pelvic pain syndrome, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
12. A method according to claim 11 , wherein the compound is administered as a pharmaceutical composition comprising a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, and a and a pharmaceutically acceptable diluent, carrier or adjuvant.